AGS-16M18
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Renal Cell
Conditions
Carcinoma, Renal Cell, Kidney Neoplasms, Kidney Diseases
Trial Timeline
Oct 1, 2008 → Apr 1, 2010
NCT ID
NCT00816686About AGS-16M18
AGS-16M18 is a phase 1 stage product being developed by Astellas Pharma for Carcinoma, Renal Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT00816686. Target conditions include Carcinoma, Renal Cell, Kidney Neoplasms, Kidney Diseases.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Renal Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00816686 | Phase 1 | Terminated |
Competing Products
20 competing products in Carcinoma, Renal Cell